PURPOSE: To develop a questionnaire that measures the impact of enteral feeding tubes (EFTs) on the quality of life (QOL) of head and neck cancer (HNC) patients METHODS: The development of the questionnaire (QOL-EF) was done in four phases. Phase 1-3 included: (1) literature review and consultation with an expert focus group (item generation), (2) pilot-testing in 12 patients and, (3) judgmental item reduction. In phase 4, the QOL-EF, FACT-H&N, and UW-QOL were administered to a cross-sectional group of HNC patients on active EFT feeding to test the reliability and validity of the QOL-EF. RESULTS: A 20-item QOL-EF was developed. In phase 4, 72 patients were accrued over 2.5 years, 31 of which were part of the test-retest subgroup. Cronbach's α for the QOL-EF was 0.73, and test-retest reliability was 0.83. Moderate correlations were observed between scores for the QOL-EF and both the FACT-H&N (-0.58) and the UW-QOL (-0.42). CONCLUSIONS: The QOL-EF is a treatment-specific QOL instrument developed and validated for use in HNC patients with EFTs. It may become an important tool in evaluating treatment outcomes and complications in these patients.
PURPOSE: To develop a questionnaire that measures the impact of enteral feeding tubes (EFTs) on the quality of life (QOL) of head and neck cancer (HNC) patients METHODS: The development of the questionnaire (QOL-EF) was done in four phases. Phase 1-3 included: (1) literature review and consultation with an expert focus group (item generation), (2) pilot-testing in 12 patients and, (3) judgmental item reduction. In phase 4, the QOL-EF, FACT-H&N, and UW-QOL were administered to a cross-sectional group of HNC patients on active EFT feeding to test the reliability and validity of the QOL-EF. RESULTS: A 20-item QOL-EF was developed. In phase 4, 72 patients were accrued over 2.5 years, 31 of which were part of the test-retest subgroup. Cronbach's α for the QOL-EF was 0.73, and test-retest reliability was 0.83. Moderate correlations were observed between scores for the QOL-EF and both the FACT-H&N (-0.58) and the UW-QOL (-0.42). CONCLUSIONS: The QOL-EF is a treatment-specific QOL instrument developed and validated for use in HNC patients with EFTs. It may become an important tool in evaluating treatment outcomes and complications in these patients.
Authors: Louise Gee; Janice Abbott; Anna Hart; Steven P Conway; Christine Etherington; A Kevin Webb Journal: J Cyst Fibros Date: 2005-03 Impact factor: 5.482
Authors: C Roberge; M Tran; C Massoud; B Poirée; N Duval; E Damecour; D Frout; D Malvy; F Joly; P Lebailly; M Henry-Amar Journal: Br J Cancer Date: 2000-01 Impact factor: 7.640
Authors: Maria Cristina Cuerda; Antonio Apezetxea; Lourdes Carrillo; Felipe Casanueva; Federico Cuesta; Jose Antonio Irles; Maria Nuria Virgili; Miquel Layola; Luis Lizan Journal: Patient Prefer Adherence Date: 2016-11-04 Impact factor: 2.711
Authors: Teresa E Brown; Merrilyn D Banks; Brett G M Hughes; Charles Y Lin; Lizbeth M Kenny; Judith D Bauer Journal: Br J Cancer Date: 2017-05-23 Impact factor: 7.640
Authors: Antonio Apezetxea; Lourdes Carrillo; Felipe Casanueva; Cristina de la Cuerda; Federico Cuesta; Jose Antonio Irles; Maria Nuria Virgili; Miquel Layola; Luis Lizán Journal: J Patient Rep Outcomes Date: 2018-05-30